Cargando…

Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease

Background. This study was performed to investigate the influence of a short-term treatment with pioglitazone versus placebo on inflammatory activation of mononuclear cells (mRNA expression/protein secretion of inflammatory markers). Methods and Results. Sixty-three patients with well-controlled typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfützner, Andreas, Weise, Alexander, Pfützner-Riehn, Elisabeth, Lübben, Georg, Morcos, Michael, Karagiannis, Efstrathios, Weber, Matthias, Forst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144663/
https://www.ncbi.nlm.nih.gov/pubmed/21808640
http://dx.doi.org/10.1155/2011/647017
_version_ 1782209021820796928
author Pfützner, Andreas
Weise, Alexander
Pfützner-Riehn, Elisabeth
Lübben, Georg
Morcos, Michael
Karagiannis, Efstrathios
Weber, Matthias
Forst, Thomas
author_facet Pfützner, Andreas
Weise, Alexander
Pfützner-Riehn, Elisabeth
Lübben, Georg
Morcos, Michael
Karagiannis, Efstrathios
Weber, Matthias
Forst, Thomas
author_sort Pfützner, Andreas
collection PubMed
description Background. This study was performed to investigate the influence of a short-term treatment with pioglitazone versus placebo on inflammatory activation of mononuclear cells (mRNA expression/protein secretion of inflammatory markers). Methods and Results. Sixty-three patients with well-controlled type 2 diabetes (52 males, 11 females, age (Mean ± SD): 66 ± 7 yrs, disease duration: 6.6 ± 9.6 yrs, HbA1c: 6.7 ± 0.6%) were randomized to additional 45 mg of pioglitazone or placebo to their existing metformin and sulfonylurea therpay for four weeks in a double-blind study design. Protein risk marker levels (hsCRP, MMP-9, MCP-1, etc.) and the expression of NFκB subunits and NFκB-modulated cytokines from isolated peripheral monocyte/macrophages were determined at baseline and endpoint. There were no changes in HbA1c, but significant biomarker improvements were seen with pioglitazone only. The mRNA marker expression was downregulated by pioglitazone and further up-regulated with placebo (e.g., P105 pioglitazone: −19%/placebo: +6%, RelA: −20%/+2%, MMP−9: −36%/+9%, TNFα: −10%/+14%, P < 0.05 between groups in all cases). Conclusions. Pioglitazone very rapidly down-regulated the activated state of peripheral monocytes/macrophages as assessed by mRNA expression of NFκB and NFκB-modulated cytokines and decreased plasma levels of cardiovascular risk marker proteins independent of glycemic control.
format Online
Article
Text
id pubmed-3144663
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31446632011-08-01 Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease Pfützner, Andreas Weise, Alexander Pfützner-Riehn, Elisabeth Lübben, Georg Morcos, Michael Karagiannis, Efstrathios Weber, Matthias Forst, Thomas PPAR Res Clinical Study Background. This study was performed to investigate the influence of a short-term treatment with pioglitazone versus placebo on inflammatory activation of mononuclear cells (mRNA expression/protein secretion of inflammatory markers). Methods and Results. Sixty-three patients with well-controlled type 2 diabetes (52 males, 11 females, age (Mean ± SD): 66 ± 7 yrs, disease duration: 6.6 ± 9.6 yrs, HbA1c: 6.7 ± 0.6%) were randomized to additional 45 mg of pioglitazone or placebo to their existing metformin and sulfonylurea therpay for four weeks in a double-blind study design. Protein risk marker levels (hsCRP, MMP-9, MCP-1, etc.) and the expression of NFκB subunits and NFκB-modulated cytokines from isolated peripheral monocyte/macrophages were determined at baseline and endpoint. There were no changes in HbA1c, but significant biomarker improvements were seen with pioglitazone only. The mRNA marker expression was downregulated by pioglitazone and further up-regulated with placebo (e.g., P105 pioglitazone: −19%/placebo: +6%, RelA: −20%/+2%, MMP−9: −36%/+9%, TNFα: −10%/+14%, P < 0.05 between groups in all cases). Conclusions. Pioglitazone very rapidly down-regulated the activated state of peripheral monocytes/macrophages as assessed by mRNA expression of NFκB and NFκB-modulated cytokines and decreased plasma levels of cardiovascular risk marker proteins independent of glycemic control. Hindawi Publishing Corporation 2011 2011-07-26 /pmc/articles/PMC3144663/ /pubmed/21808640 http://dx.doi.org/10.1155/2011/647017 Text en Copyright © 2011 Andreas Pfützner et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Pfützner, Andreas
Weise, Alexander
Pfützner-Riehn, Elisabeth
Lübben, Georg
Morcos, Michael
Karagiannis, Efstrathios
Weber, Matthias
Forst, Thomas
Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
title Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
title_full Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
title_fullStr Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
title_full_unstemmed Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
title_short Downregulation of the Proinflammatory State of Circulating Mononuclear Cells by Short-Term Treatment with Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
title_sort downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144663/
https://www.ncbi.nlm.nih.gov/pubmed/21808640
http://dx.doi.org/10.1155/2011/647017
work_keys_str_mv AT pfutznerandreas downregulationoftheproinflammatorystateofcirculatingmononuclearcellsbyshorttermtreatmentwithpioglitazoneinpatientswithtype2diabetesmellitusandcoronaryarterydisease
AT weisealexander downregulationoftheproinflammatorystateofcirculatingmononuclearcellsbyshorttermtreatmentwithpioglitazoneinpatientswithtype2diabetesmellitusandcoronaryarterydisease
AT pfutznerriehnelisabeth downregulationoftheproinflammatorystateofcirculatingmononuclearcellsbyshorttermtreatmentwithpioglitazoneinpatientswithtype2diabetesmellitusandcoronaryarterydisease
AT lubbengeorg downregulationoftheproinflammatorystateofcirculatingmononuclearcellsbyshorttermtreatmentwithpioglitazoneinpatientswithtype2diabetesmellitusandcoronaryarterydisease
AT morcosmichael downregulationoftheproinflammatorystateofcirculatingmononuclearcellsbyshorttermtreatmentwithpioglitazoneinpatientswithtype2diabetesmellitusandcoronaryarterydisease
AT karagiannisefstrathios downregulationoftheproinflammatorystateofcirculatingmononuclearcellsbyshorttermtreatmentwithpioglitazoneinpatientswithtype2diabetesmellitusandcoronaryarterydisease
AT webermatthias downregulationoftheproinflammatorystateofcirculatingmononuclearcellsbyshorttermtreatmentwithpioglitazoneinpatientswithtype2diabetesmellitusandcoronaryarterydisease
AT forstthomas downregulationoftheproinflammatorystateofcirculatingmononuclearcellsbyshorttermtreatmentwithpioglitazoneinpatientswithtype2diabetesmellitusandcoronaryarterydisease